drugset / Trial / NCT01879332

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

NCT01879332

Phase 1 Completed 16 enrolled Bial - Portela C S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled, sequential multiple ascending dose study to determine a maximum tolerated dose

Timeline

Start
2006-12
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 3000 mg Oral
Subject Eslicarbazepine acetate Unknown 3600 mg Oral

Indications